tiprankstipranks
Trending News
More News >

Tissue Regenix Awards Share Options to Executives

Story Highlights
Tissue Regenix Awards Share Options to Executives

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Tissue Regenix ( (GB:TRX) ).

Tissue Regenix has announced the grant of share options to key executives, including CEO Daniel Lee and EMEA Business Director Kirsten Lund, under its annual Share Incentive Plan. These options, which are linked to performance targets, reflect the company’s commitment to aligning executive rewards with shareholder interests and may influence the company’s future performance and stakeholder confidence.

More about Tissue Regenix

Tissue Regenix is a leading medical device company specializing in regenerative medicine. The company utilizes its patented decellularisation technology (dCELL®) to create acellular tissue scaffolds from animal and human soft tissue, which are not rejected by the patient’s body and can be used to repair damaged body structures. Their products are applied in areas such as sports medicine, foot and ankle injuries, and wound care.

Average Trading Volume: 59,049

Technical Sentiment Signal: Sell

Current Market Cap: £20.3M

See more data about TRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1